Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 4/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
| ▸ | KLK7 | P49862 | 3/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13499740 | 0.95 | SLC1A3 (0.36) | SLC1A3SLC1A2SLC1A1CTSKCTSS | |
| SCHEMBL13501743 | 0.86 | SLC1A3 (0.41) | SLC1A3SLC1A2SLC1A1CTSKCTSS | |
| SCHEMBL13435118 | 0.84 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1CTSKMETAP2 | |
| SCHEMBL13461544 | 0.83 | SLC1A3 (0.39) | SLC1A3SLC1A2SLC1A1CTSKMETAP2 | |
| SCHEMBL13499749 | 0.81 | SLC1A3 (0.49) | SLC1A3SLC1A2SLC1A1CTSKMETAP2 | |
| SCHEMBL13909181 | 0.81 | SLC1A3 (0.37) | SLC1A3SLC1A2SLC1A1CTSKMETAP2 | |
| SCHEMBL13499744 | 0.79 | SLC1A3 (0.38) | SLC1A3SLC1A2SLC1A1CTSKMETAP2 | |
| SCHEMBL13501749 | 0.79 | CNR2 (0.39) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13435110 | 0.78 | SLC1A3 (0.37) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13499733 | 0.76 | TSHR (0.34) | CTSKMETAP2CTSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-7655647-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | SLC1A3 801/4885SLC1A2 537/4885SLC1A1 743/4885 |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | SLC1A3 864/4885SLC1A2 667/4885SLC1A1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.